2024
Cost‐effectiveness of sutimlimab in cold agglutinin disease
Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost‐effectiveness of sutimlimab in cold agglutinin disease. American Journal Of Hematology 2024, 99: 1475-1484. PMID: 38733355, DOI: 10.1002/ajh.27358.Peer-Reviewed Original ResearchPrimary cold agglutinin diseaseCold agglutinin diseaseStandard-of-careIncremental cost-effectiveness ratioUS willingness-to-pay thresholdRare autoimmune hemolytic anemiaPhase 3 studyWillingness-to-pay thresholdsAutoimmune hemolytic anemiaTime-limited treatmentHuman monoclonal antibodyCold-reactive antibodiesBinding to red blood cellsFollow-up dataCost-effectiveness ratioComplement-mediated hemolysisDeterministic sensitivity analysisHealth resource utilizationProbabilistic sensitivity analysesTransfusion-DependentClinical remissionTransfusion supportImprove quality of lifeRed blood cellsHemolytic anemia
2021
Risk of Disseminated Gonococcal Infections With Terminal Complement Blockade
Graciaa SH, Graciaa DS, Yildirim I, Chonat S. Risk of Disseminated Gonococcal Infections With Terminal Complement Blockade. Journal Of Pediatric Hematology/Oncology 2021, 44: e493-e495. PMID: 33560079, PMCID: PMC8556643, DOI: 10.1097/mph.0000000000002075.Peer-Reviewed Original ResearchConceptsTerminal complement blockadeComplement blockadeGonococcal infectionClonal hematopoietic stem cell disordersDisseminated gonococcal infectionHematopoietic stem cell disordersQuality of lifeStem cell disordersParoxysmal nocturnal hemoglobinuriaComplement protein C5Complement-mediated hemolysisProphylactic antibioticsIntravascular hemolysisAppropriate immunizationsAzithromycin resistanceCell disordersNocturnal hemoglobinuriaNeisseria gonorrhoeaeProtein C5Infection riskPatientsMonoclonal antibodiesNeisseria meningitidisBlockadeInfection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply